We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will summarize the bulls’ thesis on EW. Edwards Lifesciences Corporation (EW)'s ...

A critical component of Edwards’ success is its leadership in the $7 billion transcatheter aortic valve replacement (TAVR) market, where it holds over 50% market share. This segment generates ...

A critical component of Edwards' success is its leadership in the $7 billion transcatheter aortic valve replacement (TAVR) market, where it holds over 50% market share. This segment generates roughly ...

For a while there, it seemed like a crudely drawn webcomic had DreamWorks Animation’s number. In an unflattering contrast to the imaginative movies that Pixar was making in the ‘00s ...

Edwards Lifesciences Corporation (NYSE ... Wise suggests that recent conversations with six Transcatheter aortic valve replacement (TAVR) physicians and a follow-up survey of thirty doctors ...

citing a turnaround in its position in the market for transcatheter aortic valve replacement (TAVR). Analyst Rick Wise argued that Edwards Lifesciences (NYSE:EW) shares have mainly remained range ...

Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences is likely to have witnessed continued growth in procedures across the United States and worldwide. Continued ...

In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW ... including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters.